Industry – Page 32 – Swanson Reed | Specialist R&D Tax Advisors

Nano RED Receives Phase 1 SBIR Award

Nano RED is a biotechnology startup which exists to bring the nanotechnology revolution to medicine. In the face of the COVID-19 pandemic, they began development of precision medicine platforms to aid in treatment of respiratory viral illnesses. Their platform targets key elements that are present across all variants of the virus.

Nano RED has since received a Phase 1 Small Business Innovation Research award from the National Science Foundation for this work.

Nano RED beat out four other finalists, two of which are also in the healthcare space. As winners of the contest, co-founders Gang Xin, Karthika Divakaran, and Dr. Jonathan Ebben have earned a spot in the upcoming meeting with Silicon Valley investors this fall. Pressure Chamber participants have gone on to collectively raise more than $500 million from investors.

Their platform can shield the immunocompromised and most vulnerable, be deployed rapidly, and can be iterated to prevent and treat emerging respiratory viruses. They are also developing a second, complementary cancer immunotherapy platform to help physicians to release therapies directly into tumors and the tumor microenvironment.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

ATOMIC Receives $1.5M from NSF Funding

The Center for Atomically Thin Multifunctional Coatings (ATOMIC) has received a grant from the National Science Foundation that will help them to further expand. This center brings together university, industry, and government partners to develop atom-thin 2D coatings with wide-ranging industrial applications.

ATOMIC was launched in 2015 and has 13 industry partners and five government partners. It is the only NSF center dedicated to the development of 2D coatings. They have won $1.5 million in Phase II funding which will allow them to add new academic partners – starting with Boise State University – and new industry partners.

The research is focused on designing and developing 2D materials with unique physical, optical, electrical and chemical properties. Ranges in thickness vary from to a few atoms can enable new technologies to address corrosion, oxidation, abrasion resistance and more.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

FourthWall Testing Partners Up with NOVA

Michigan Patent of the Month - July 2021

FourthWall Testing, LLC has announced a partnership with Nova Mentis Life Science Corp (NOVA). Together, they have established a Serotonin Research Center at FourthWall’s Florida headquarters.

This collaboration will enable the companies to develop assays to measure serotonin levels in blood, feces, and urine in patients with autism spectrum disorder (ASD). Serotonin is a key hormone which allows brain cells and other nervous system cells to communicate with each other. ASD categorizes a diverse group of conditions characterized by some degree of difficulty with social interaction and communication as well as atypical patterns of activities and behaviors. Their collaborative neuroinflammatory research program is based on identifying biomarkers that can be used to confirm the therapeutic efficacy of NOVA’s proprietary psilocybin-based drug portfolio. They have plans to develop and launch a longitudinal data bank to support the large-scale studies of the microbiome, developmental disorder genetics serotonin activity levels, and behavioral metrics as they relate to ASD, with an additional focus on individuals diagnosed with ASD and fragile x syndrome (FXS)

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Coeptis Therapeutics, Inc. Acquires CD38 Tech from VyGen-Bio

Minnesota Patent of the Month - June 2021

Coeptis Therapeutics, Inc. is a pharmaceutical company focused on developing innovative technologies to break past traditional therapeutic paradigms. Recently, they have announced to exercise their option to acquire ownership in two technology assets that target CD38 cancers. These technologies come from VyGen-Bio, Inc. – a subsidiary of Vycellix, Inc.

The first technology – a CD38-GEAR-NK – is a cell therapy product in development to protect CD38-NK (natural killer) cells from destruction. The second is CD38-Diagnostic, an in vitro diagnostic tool to help identify cancer patients who may be appropriate candidates for the anti-CD38 mAB therapy.

This move follows Coeptis’ entry into two separate exclusive option agreements with VyGen-Bio, Inc. This co-development will help in their treatment of cancers associated with CD38 with the first indication expected to be multiple myeloma.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Canoo Gears up for Production of EVs

Canoo – a successful electric vehicle startup – has made moves to gear up for production. With plans to release electric minivans in 2022, and commercial vehicles soon after, they have hired hundreds of employees and started gathering suppliers needed for production.

They have plans to build what they call a “Mega Micro Factory” for pickup trucks and multipurpose delivery vehicles. This facility will be based in Oklahoma. The state has promised $300 million in undiluted financial incentives to support Phase II of their facilities and manufacturing.

Aquila said about one-third of Oklahoma’s investment will be available within the first 36 months. These funds will help the company progress in the transition to the gamma phase, which means Canoo is preparing to launch. Canoo increases its workforce from 230 to 656 each year, 70% of which are hardware and software engineers. Startup operating costs increased from $19.8 million year-on-year to $104.3 million, most of which was due to research and development.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

CenExel Acquires Advanced Memory Research Institute

CenExel Clinical Research, Inc. has announced their acquisition of Advanced Memory Research Institute (CenExel AMRI)- the largest Alzheimer’s Disease clinical research site in the Northeast. CenExel AMRI conducts Phase I- IV studies focused on Alzheimer’s Disease, Memory Loss, and Dementia research.

CenExel is known for their scientific support in the design and execution of clinical trials. With the acquisition of AMRI, they will further their experience in CNS trials. Now, CenExel Centers of Excellence network now comprises 11 of the most proficient clinical research sites in the country ranging from neurology, pain, sleep, and clinical studies.

CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to reduce costs and development times for innovative therapies which may advance patient care. Acquisition of a variety of clinical experts and research sites helps to bring together talent and resources for improved development pipelines.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

New York Commits 7.5M to Clean Energy Affordable Housing

Wisconsin Patent of the Month - May 2021

The Clean Energy Initiative announces $7.5 million in funding to create 600 energy efficient and all-electric affordable housing units in New York. The goal is to bring together highly efficient, all electric new construction as well as adaptive reuse projects to breathe carbon neutral affordable housing.

All space heating, cooling and domestic hot water appliances and equipment must be high-performance electric such as, but not limited to, air source or water source heat pumps or variable refrigerant flow (VRF) units and the buildings must achieve advanced levels of Energy Star Certification.

This pilot project is supported as a collaborative effort between New York State Homes and Community Renewal and the New York State Energy Research and Development Authority (NYSERDA). They believe this plan will help contribute to New York’s goal of an 85% reduction in greenhouse gas emissions by 2050.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Green Stream Farms Receives $250K to Expand Algae Harvest

Green Stream Farms, an algae farmer, has been awarded economic assistance to expand its processing operations and create jobs in their home state. They have focused their efforts on growing algae on 96 acres of lined ponds, but with the way the world is heading, the demand for algae is higher than ever – and higher than their facility can support right now.

The farm can support an expansion, as they have access to the necessary water supply – but new equipment, buildings, and manpower are a limitation. With the economic assistance, they will be able to begin construction and upgrades to move into industrial scale growth. Assistance comes in the form of a $250,000 grant and is expected to more than double their annual harvest from 250 tons to 700 tons by 2022.

Green Stream customers use the algae primarily in two vertical markets, as a feed supplement for healthier livestock and for Omega-3 enriched nutraceutical products available at many retail outlets. Expanding this agricultural sector will further help even out the seasonality of agricultural jobs and create year-round opportunities for employment.

Luna County is the ideal location for Green Stream’s micro-algae product due to its climate and moderate overnight temperatures. The site is the second largest outdoor algae farm in the world with harvesting occurring nine or ten months out of the year, while ponds hibernate in the hotter summer months. Scaling up to double their harvest will require great amounts of R&D to ensure the product maintains its stellar quality.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Astellas Pharma Inc. to Fund LabCentrals Future Innovator Prize

Mississippi Patent of the Month - August 2021

Astellas Pharma Inc. has partnered with LabCentral – a launchpad for early stage life science startups – to fund and encourage innovation in the industry. Through their subsidiary, Astellas Venture Management LLC, they will collaborate on the “Future Innovator Prize” which goes towards entrepreneurial scientists. The prize goes beyond funding, offering one-year usage of LabCentral’s state-of-the-art facility in Cambridge and access to Astellas’ R&D capabilities and business leaders.

Collaborations like this provide the chance for startups to fund and engage in R&D to advance the industry. Companies can submit their proposals until September 13, at which point they will be reviewed by a selection committee. 5 finalists will be selected to pitch in front of Astellas senior leadership on October 28th. Of these, the prize will be awarded to two pioneering scientists with innovative research that complements Astellas’ areas of interests, including oncology, immunology, and neuroscience.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Infinity Labs Obtains Second Phase II Agility Prime Contract

Ohio’s Infinity Labs is the first to receive two Phase II Agility Prime contracts. Agility Prime is the Air Force’s development of electric vertical takeoff and landing (eVTOL) aircraft – or flying cars. This makes Infinity Labs the first to receive two Phase II and three Phase I awards in the Agility Prime project.

The latest Phase II award is set to focus on the analysis of their emerging “Urban Air Mobility” (UAM) battery technologies, and the Dayton company’s effort establishes an open-source modeling, simulation, and analysis toolset. Research into the potential of reusing and recycling batteries to obtain second-life applications will advance the industry and expand Infinity Labs reach. This award comes with $750,000 over a 15-month period.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.